ILLIMIS
Live / Registered — Registered (as of 04 Jul 2023)
What this means for you
Registered since 04 Jul 2023. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79342263
- Registration number
- 7095522
- Mark type
- Word mark
- Filed
- 17 Mar 2022
- Published for opposition
- 18 Apr 2023
- Registered
- 04 Jul 2023
- Attorney of record
- Jong Park
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of auto-immune diseases; pharmaceutical agents affecting sensory organs; pharmaceutical agents affecting peripheral nervous system; pharmaceutical preparations for activating cellular function; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for respiratory organs; pharmaceutical preparations for the prevention of disorders of the nervous system; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for the treatment of inflammatory diseases; ophthalmic preparations; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for the treatment of degenerative brain disease; pharmaceutical preparations for the treatment of brain dysfunction; pharmaceutical preparations for the treatment of stroke; pharmaceutical preparations for the treatment of cerebrovascular disease; pharmaceutical preparations for the treatment of dementia; pharmaceutical preparations for the treatment of Alzheimer's disease; pharmaceutical preparations for use in the treatment of solid tumors and growths, hemolytic diseases and disorders, amyloidosis, metabolic diseases and disorders, lupus, and inflammation and autoimmune diseases and disorders
- Class 042 — Scientific and technological services: Pharmaceutical product development; pharmaceutical research and development of medicines in the field of age-related diseases/disorders and degenerative diseases; pharmaceutical research and development of medicines in the field of chronic malady/disease and dysfunction; scientific research for medical purposes in the field of gene therapy; medical scientific research in the field of brain disease; medical scientific research in the field of neurological diseases; biotechnology research and scientific and pharmaceutical research in the antibody field; biological research; scientific research in the field of cancer disease; remote monitoring and quality control inspection for others of active substances in the pharmaceutical research field and scientific analysis of active substances in the pharmaceutical research field; research for quality inspection related to human hygiene management for medical research purposes; scientific and medical research of autoimmune disease; development of pharmaceutical preparations for cell therapy; stem cell collection for medical research; cell processing and culture for medical research; pharmaceutical research and development of medicines in the field of inflammatory disease; pharmaceutical research and development of medicines in the field of eye disease; pharmaceutical research and development of medicines in the field of amyloidosis; consultancy pertaining to pharmacology relating to pharmaceutical quality control; providing information on the research of medical products relating to pharmaceutical quality control
Owner
Prosecution history
- 31 Oct 2023 — FINAL DECISION TRANSACTION PROCESSED BY IB
- 06 Oct 2023 — FINAL DISPOSITION NOTICE SENT TO IB
- 06 Oct 2023 — FINAL DISPOSITION PROCESSED
- 04 Oct 2023 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 04 Jul 2023 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 04 Jul 2023 — REGISTERED-PRINCIPAL REGISTER
- 10 May 2023 — LIMITATION FROM THE IB EXAMINED AND ENTERED
- 25 Apr 2023 — NOTIFICATION PROCESSED BY IB
- 18 Apr 2023 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 18 Apr 2023 — PUBLISHED FOR OPPOSITION
- 05 Apr 2023 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
- 05 Apr 2023 — NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
- 29 Mar 2023 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 21 Mar 2023 — REFUSAL PROCESSED BY IB
- 11 Mar 2023 — APPROVED FOR PUB - PRINCIPAL REGISTER